Compare Baxter International Inc (BAX) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Celsius Holdings, Inc. — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Celsius Holdings, Inc. trades at $28.03 (market cap $6.89B). The key difference: Baxter International Inc is far larger — about 2.1× Celsius Holdings, Inc.'s market cap, and Baxter International Inc pays a 0.14% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| BAX | CELH | |
|---|---|---|
Market Cap | $14.36B | $6.89B |
Sector | Health | Consumer Staples |
52-Week High | $28.35 | $64.86 |
52-Week Low | $15.80 | $23.77 |
Enterprise Value | $21.88B | $8.68B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
CELH trades at $27.77, up 16.83% in 24 hours, but technical indicators signal a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates, with revenue growth slowing to 11% year-over-year. Recent news includes an analyst downgrade and leadership changes amid an organizational realignment. Valuation metrics remain elevated with a P/E of 120.74 and P/S of 2.37.
The outlook is mixed: strong analyst consensus (95.65% buy ratings) and a $44.08 price target suggest upside, but risks include core brand weakness, margin pressure, and a pending legal investigation. Investors should weigh growth potential from Alani Nu and Rockstar integrations against execution challenges and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
